Skip to content
10-K

Annual Report

Oncternal Therapeutics, Inc.

0000950170-24-027984

← back to feed
Filed
Mar 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 1, 2024 2.96M sh
Shares Diluted FY 2023 · Dec 31, 2023 2.94M sh
Shares Diluted restated FY 2023 · Dec 31, 2022 2.63M sh
Operating Cash Flow FY 2023 · Dec 31, 2023 −$32.16M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$36.7M
Short Term Investments FY 2023 · Dec 31, 2023 $27.56M
Short Term Investments FY 2023 · Dec 31, 2022 $26.58M
Cash And Equivalents FY 2023 · Dec 31, 2023 $6.7M
Cash And Equivalents FY 2023 · Dec 31, 2022 $37.14M
Stockholders Equity FY 2023 · Dec 31, 2023 $30.05M
Stockholders Equity FY 2023 · Dec 31, 2022 $60.97M
Stockholders Equity FY 2023 · Dec 31, 2021 $88.12M
Current Liabilities FY 2023 · Dec 31, 2023 $5.2M
Current Liabilities FY 2023 · Dec 31, 2022 $7.68M
Total Liabilities FY 2023 · Dec 31, 2023 $6.68M
Total Liabilities FY 2023 · Dec 31, 2022 $7.68M
Current Assets FY 2023 · Dec 31, 2023 $36.06M
Current Assets FY 2023 · Dec 31, 2022 $67.29M
Total Assets FY 2023 · Dec 31, 2023 $36.73M
Total Assets FY 2023 · Dec 31, 2022 $68.65M
Eps Diluted FY 2023 · Dec 31, 2023 −$13.43
Eps Diluted restated FY 2023 · Dec 31, 2022 −$16.80
Eps Basic FY 2023 · Dec 31, 2023 −$13.43
Eps Basic restated FY 2023 · Dec 31, 2022 −$16.80
Net Income FY 2023 · Dec 31, 2023 −$39.48M
Net Income FY 2023 · Dec 31, 2022 −$44.17M
Operating Income FY 2023 · Dec 31, 2023 −$41.71M
Operating Income FY 2023 · Dec 31, 2022 −$44.95M
Revenue FY 2023 · Dec 31, 2023 $785K
Revenue FY 2023 · Dec 31, 2022 $1.49M